Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report.

advanced cutaneous squamous cell carcinoma cemiplimab immunotherapy skin cancer squamous cell carcinoma

Journal

Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 29 03 2021
revised: 16 11 2021
accepted: 03 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 25 12 2021
Statut: epublish

Résumé

This is a case of a 60-year-old man living with HIV who presented with advanced cutaneous squamous cell carcinoma. After workup, medical and surgical treatment, and disease recurrence, he achieved a complete response with no unexpected toxicities after immunotherapy with cemiplimab.

Identifiants

pubmed: 34950481
doi: 10.1002/ccr3.5228
pii: CCR35228
pmc: PMC8673230
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e05228

Informations de copyright

© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

None.

Références

Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Prog Tumor Res. 2015;42:55-66
pubmed: 26382943
Nature. 1993 Apr 22;362(6422):758-61
pubmed: 8469287
J Immunother Cancer. 2019 Nov 15;7(1):305
pubmed: 31730010
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
AIDS. 2014 May 15;28(8):1181-91
pubmed: 24901259
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
PLoS One. 2015 Jun 17;10(6):e0129550
pubmed: 26083524
Oncotarget. 2017 Feb 21;8(8):13116-13125
pubmed: 28061450
JAMA Oncol. 2019 Sep 1;5(9):1332-1339
pubmed: 31154457
Cancer Biol Med. 2017 Aug;14(3):254-270
pubmed: 28884042
Clin Infect Dis. 2009 Mar 1;48(5):633-9
pubmed: 19202627
JAMA Intern Med. 2017 Nov 1;177(11):1613-1621
pubmed: 28975270
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Ann Oncol. 2018 Feb 1;29(2):517-518
pubmed: 29206889
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586

Auteurs

Abdurahman Alloghbi (A)

Department of Oncology Karmanos Cancer Institute Wayne State University Detroit Michigan USA.

James Ninia (J)

School of Medicine Wayne State University Detroit Michigan USA.

Bayan Alshare (B)

Department of Oncology Karmanos Cancer Institute Wayne State University Detroit Michigan USA.

Jeffrey Hotaling (J)

Department of Surgical Oncology Karmanos Cancer Institute Detroit Michigan USA.

Syed Raza (S)

Department of Surgical Oncology Karmanos Cancer Institute Detroit Michigan USA.

Ammar Sukari (A)

Department of Oncology Karmanos Cancer Institute Wayne State University Detroit Michigan USA.

Classifications MeSH